Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DOXIFLURIDINE AND LEUCOVORIN - AN ORAL TREATMENT COMBINATION IN ADVANCED COLORECTAL-CANCER
Autore:
BAJETTA E; COLLEONI M; DIBARTOLOMEO M; BUZZONI R; BOZZETTI F; DOCI R; SOMMA L; CAPPUZZO F; STAMPINO CG; GUENZI A; BALANT LP; ZILEMBO N; DILEO A;
Indirizzi:
IST NAZL STUDIO & CURA TUMORI,DIV MED ONCOL B,VIA VENEZIAN 1 I-20133 MILAN ITALY IST NAZL STUDIO & CURA TUMORI,DIV SURG ONCOL A I-20133 MILAN ITALY ROCHE CLIN RES MILAN ITALY UNIV GENEVA,SCH MED CH-1211 GENEVA SWITZERLAND
Titolo Testata:
Journal of clinical oncology
fascicolo: 10, volume: 13, anno: 1995,
pagine: 2613 - 2619
SICI:
0732-183X(1995)13:10<2613:DAL-AO>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-CELLS; PHASE-II; 5'-DEOXY-5-FLUOROURIDINE; CARCINOMA; FLUOROURACIL; 5'-DFUR; 5-FLUOROURACIL; MODULATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
27
Recensione:
Indirizzi per estratti:
Citazione:
E. Bajetta et al., "DOXIFLURIDINE AND LEUCOVORIN - AN ORAL TREATMENT COMBINATION IN ADVANCED COLORECTAL-CANCER", Journal of clinical oncology, 13(10), 1995, pp. 2613-2619

Abstract

Purpose: This study was designed to test the activity and feasibilityof an all-oral regimen of levo-leucovorin and doxifluridine (dFUR) inthe treatment of advanced colorectal cancer and to establish whether the pharmacokinetics of dFUR and fluorouracil (FU) are affected by demographic and/or biologic parameters. Materials and Methods: One hundred eight patients with histologically proven colorectal cancer receivedorally administered levo-leucovorin 25 mg followed 2 hours later by dFUR 1,200 mg/m(2) on days 1 to 5, with the cycle being repeated every 10 days, Results: Among 62 previously untreated patients, two completeresponses (CRs) and 18 partial responses (PRs) were observed (overallresponse rate, 32%; 95% confidence interval, 21% to 45%). The median response duration was 4 months (range, 2 to 13) and the median survival time, 14 months, Among 46 pretreated patients, there were three CRs and three PRs (response rate, 13%; 95% confidence interval, 5% to 26%). In this group of patients, the median response duration was 4 months(range, 1 to 12)and the median survival time, 12 months. No toxic deaths were observed, The only World Health Organization (WHO) grade 3 to4 side effect was diarrhea (32 patients). Conclusion: This regimen isactive in previously untreated colorectal cancer patients and combines good compliance with safety. Limited but definite efficacy was also detected in the patients previously treated with FU, which suggests incomplete cross-resistance between the two drugs. The pharmacokinetic results suggest that the conversion rate of dFUR to FU increases between days 1 and 5, but that FU levels remain low in comparison to those measured after classical FU therapy. Under the experimental conditions used in this study, the interpatient variability of pharmacokinetic parameters remains largely unexplained by the tested variables. (C) 1995by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 13:06:45